Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus plantarum SQ001
- Development stage
- Preclinical
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum SQ001 is a specific strain of *Lactobacillus plantarum* isolated from the cecum of hyperuricemia (HUA) geese. It is being investigated as a probiotic therapy for hyperuricemia and gout. The strain works by improving the gut microbial community and facilitating hydrolase-mediated degradation of purine nucleosides. Mechanistically, it promotes nucleoside uptake and hydrolysis through its nucleoside hydrolase gene, downregulates hepatic xanthine oxidase (a key enzyme in uric acid synthesis), and modulates renal transporters by downregulating the reabsorption protein GLUT9 and enhancing the expression of the renal excretion protein ABCG2. These actions collectively contribute to reducing serum uric acid levels.
02
Targets
ABCG2 (Breast cancer resistance protein)GLUT9 (Glucose transporter type 9)NH4+ (Ammonium ion)XO (Xanthine Oxidoreductase)
Beyond the preview
Go deeper on Lactobacillus plantarum SQ001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus plantarum SQ001.